Answers are grounded in this paper and cite their sources.
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with limited treatment options and poor patient outcomes. The lack of clinically relevant large animal models hinders the investigation of early disease mechanisms and translational therapeutic strategies. In this study, we present a genetically engineered porcine PDAC model involving pancreas-specific activation of latent KRASG12D alone (KC) or in combination with TP53R167H (KPC), developed in a midipig background. KC pigs predominantly developed progressive acinar-to-ductal metaplasia (ADM), whereas KPC pigs showed accelerated tumour progression, including PanINs, invasive carcinoma, perineural invasion, and early lymphatic dissemination. Histopathological and molecular analyses revealed pronounced intra- and inter-tumour heterogeneity, a complex stromal microenvironment, and expression of key PDAC markers. Tumours exhibited early alterations in oncogenic KRAS signalling, including increased dosage and differential expression of isoforms, together with dysregulation of tumour suppressor networks involving p16 and TP53 family members. Single-cell transcriptomics and flow cytometric analyses demonstrated an organised and functionally active immune landscape in early lesions, characterised by infiltrating effector and regulatory T-cell populations. Porcine pancreatic cancer cell lines (PoPaCa) were established from KC and KPC tumours, recapitulating key genetic and transcriptional features of the primary lesions. Exploratory drug screening demonstrated heterogeneous responses to clinically relevant and experimental compounds. Responses to gemcitabine and paclitaxel overlapped qualitatively with those observed in human PDAC cell lines, whereas pronounced sensitivity to the GPX4 inhibitor RSL3 and partial responsiveness to trametinib identified testable therapeutic phenotypes for further validation. Together, this genetically engineered porcine PDAC model captures early molecular, cellular, and microenvironmental features of pancreatic tumorigenesis and provides a translational platform to study disease initiation, tumour heterogeneity, immune interactions, and therapeutic response beyond the constraints of rodent models.
No takes yet. Share an insight, caveat, or question.
Flisikowska et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: